Stay updated on Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.
Latest updates to the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page
- Check2 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; this is a minor site update that does not affect study content or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%
- Check9 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedExpanded and reorganized the Locations section to include multiple sites across the US, Australia, and Canada, with an updated revision to v3.3.3.SummaryDifference1%
- Check53 days agoChange DetectedWording updated to clarify that PubMed publications are auto-filled and may not be about the study, and the page revision is now v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check60 days agoChange DetectedRemoval of the funding lapse banner regarding government funding and NIH Clinical Center operations; core trial information remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%
- Check81 days agoChange DetectedNo significant additions or deletions were detected on the page; the content remains focused on study details and eligibility criteria.SummaryDifference0.4%
- Check103 days agoChange DetectedSummary of changes: updated operating-status notice and a version bump to v3.2.0, replacing the previous v3.1.0.SummaryDifference3%
Stay in the know with updates to Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.